Table 2.
Univariate and multivariate analysis for EFS and OS in patients without gemtuzumab ozogamicin treatment.
| Variables | OS |
EFS |
||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Univariate analyses | ||||
| ANXA5 (high versus low) | 2.097 (1.146–3.838) | 0.016 | 2.232 (1.218–4.093) | 0.009 |
| Age (⩾10 versus <10 years) | 1.017 (0.565–1.833) | 0.954 | 0.948 (0.526–1.709) | 0.859 |
| Sex (male versus female) | 1.288 (0.715–2.32) | 0.399 | 1.271 (0.706–2.289) | 0.425 |
| Ethnicity (Hispanic or Latino versus others) | 1.657 (0.854–3.213) | 0.135 | 1.507 (0.777–2.924) | 0.225 |
| WBC (⩾50 versus <50 × 109/l) | 1.003 (0.552–1.821) | 0.992 | 1.315 (0.723–2.393) | 0.37 |
| BM blasts (⩾70 versus <70%) | 0.957 (0.532–1.72) | 0.883 | 0.979 (0.545–1.76) | 0.943 |
| PM blasts (⩾50 versus <50%) | 0.718 (0.395–1.305) | 0.277 | 0.865 (0.476–1.571) | 0.634 |
| NPM1 (mutated versus wild type) | 0.578 (0.179–1.867) | 0.36 | 0.547 (0.169–1.767) | 0.313 |
| MLL (mutated versus wild type) | 1.807 (0.869–3.756) | 0.113 | 1.683 (0.809–3.5) | 0.163 |
| FLT3-ITD (positive versus negative) | 1.163 (0.576–2.351) | 0.673 | 1.288 (0.637–2.603) | 0.481 |
| CBFβ-MYH11 (positive versus negative) | 0.598 (0.214–1.669) | 0.326 | 0.687 (0.245–1.925) | 0.476 |
| RUNX1-RUNX1T1 (positive versus negative) | 0.507 (0.2–1.284) | 0.152 | 0.404 (0.159–1.026) | 0.057 |
| WT1 (mutated versus wild type) | 1.211 (0.433–3.385) | 0.715 | 1.4 (0.498–3.933) | 0.523 |
| Risk (poor versus non-poor) | 2.795 (1.415–5.521) | 0.003 | 3.259 (1.646–6.449) | 0.001 |
| Multivariate analyses | ||||
| ANXA5 (high versus low) | 2.687 (1.355–5.326) | 0.005 | 2.762 (1.365–5.591) | 0.005 |
| Ethnicity (Hispanic or Latino versus others) | 1.652 (0.845–3.231) | 0.142 | 1.408 (0.722–2.746) | 0.315 |
| MLL (mutated versus wild type) | 0.783 (0.335–1.828) | 0.572 | 0.709 (0.309–1.626) | 0.417 |
| FLT3-ITD (positive versus negative) | 1.343 (0.62–2.912) | 0.455 | 1.535 (0.696–3.383) | 0.288 |
| RUNX1-RUNX1T1 (positive versus negative) | 2.009 (0.572–7.06) | 0.277 | 1.884 (0.513–6.923) | 0.34 |
| Risk (poor versus non-poor) | 3.806 (1.518–9.542) | 0.004 | 4.492 (1.781–11.33) | 0.001 |
BM, bone marrow; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; PB, peripheral blood; PM, peripheral blood; non-poor, intermediate and good; WBC, white blood cell.